CompleMENTOR

Q: お住まいの国では利用できないCompleMENTORをダウンロードしたい時にはどうすればいい？

<a href="https://apkpure.com/howto/how-to-download-an-iphone-app-if-it-is-not-available-in-your-country">ここ</a>をクリック！地理的に制限されているアプリのダウンロード方法をご参考ください。

Q: CompleMENTORを実行するための最小システム要件は何？

次のリストをチェックして、CompleMENTORの最低システム要件をご確認ください。<br/><ul><li>iPhone-</li><li>iPad-</li></ul>

Free

1.0for iPhone, iPad

Alexion Pharmaceuticals, Inc.

Developer

2017年07月13日

Update Date

Health & Fitness

Category

App Store

Age Rating

Apps in this category do not contain restricted content.

Apps in this category may contain mild or occasional cartoon, fantasy or real-life violence, as well as occasional or mild adult, sexually suggestive or horrifying content and may not be suitable for children under 9 years of age.

12+

Apps in this category may contain occasional mild indecent language, frequent or intense cartoon or real-life violence, minor or occasional adult or sexually suggestive material, and simulated gambling, and may be for children under 12 years of age.

17+

You must be at least 17 years old to access this App.

Apps in this category may contain frequent and intense offensive language; Frequent and intense cartoon, fantasy or realistic violence: frequent and intense adult, scary and sexually suggestive subjects: as well as sexual content, nudity, tobacco, alcohol and drugs, may not be suitable for children under 17 years of age.

CompleMENTOR スクリーンショット

iPad

iPhone

About CompleMENTOR

The CompleMENTOR app helps physicians learn more about two ultra-rare, complement-mediated diseases – atypical HUS (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) – including disease consequences and how to identify patients.

Download this evidence-based app for expert perspectives on diagnosing and managing aHUS and PNH and to access resources that will help manage patients with aHUS and PNH. Through this app, you can also find your Alexion Nurse Case Manager, Regional Account Manager, and contact OneSource – a free program offered by Alexion for your disease, treatment, and funding questions.